Swiss Re AG Posts Record Profit, Ups Capital Returns

Swiss Re AG ((SSREY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Swiss Re’s latest earnings call struck an upbeat tone as management showcased record 2025 net income of USD 4.8 billion and a 20% ROE, well ahead of targets. Strong P&C reinsurance, solid investment returns and hefty capital returns dominated the narrative, even as weakness in Life & Health and a shrinking top line reminded investors that the turnaround is not yet complete.

Record Profit and High Returns on Equity

Swiss Re reported group net income of USD 4.8 billion for 2025, beating its USD 4.4 billion target and translating into a robust 20% ROE. Management credited disciplined underwriting, strong recurring investment income and relatively light large-loss activity outside the first quarter, underscoring improved earnings quality.

Capital Returns Surge on Strong Solvency

The board proposed an ordinary dividend of USD 8 per share, a 9% increase, alongside a USD 500 million “sustainable” buyback and an additional USD 1 billion extraordinary buyback. In total, the roughly USD 3.9 billion capital return equals about 80% of 2025 earnings, while the Swiss Solvency Test ratio remains a sturdy 250% after these actions.

P&C Re Delivers Standout Underwriting

Property & Casualty Reinsurance was the star performer, generating an insurance service result of USD 3.6 billion and a combined ratio of 79.4%, well below the sub‑85% target. Large natural catastrophe losses came in USD 1.2 billion below expectations, boosting profitability and highlighting the benefit of prior pricing and portfolio actions.

Corporate Solutions Maintains Solid Momentum

Corporate Solutions posted a full‑year combined ratio of 86.5%, comfortably better than its target of below 91%. Its insurance service result rose to USD 1.2 billion, around USD 200 million higher year on year, with management noting that on a like‑for‑like basis the combined ratio would be close to an impressive 80%.

Life & Health Re: Profitable but Under Scrutiny

Life & Health Re delivered net income of USD 1.3 billion despite extensive portfolio reviews and assumption changes that weighed on results. Management stressed that these actions should improve visibility and set the business up to reach a higher net income target of USD 1.7 billion in 2026, but investors will watch execution closely.

Stable Investment Engine Supports Earnings

The investment portfolio produced a 4.0% return on investments in 2025, with a recurring yield of 4.2% and reinvestment yields around 4.4%. Recurring investment income of about USD 4 billion underpins earnings, giving Swiss Re a steady income stream to complement underwriting profits in a still supportive interest‑rate environment.

Cost Discipline and Efficiency Drive

Swiss Re reported more than USD 100 million of cost savings in 2025 as part of its multi‑year efficiency program. The company remains on track to trim its operating cost run‑rate by USD 300 million by 2027, implying an additional USD 200 million of savings over the next two years as management keeps pressure on expenses.

Stronger Reserves and Higher Loss Picks

The group raised its initial loss assumptions by 4.6% and added roughly USD 200 million to current‑year and USD 100 million to prior‑year reserves in nominal terms. It also recycled nearly USD 1 billion of short‑tail reserve redundancies into longer‑tail IBNR, steps that bolster balance‑sheet resilience but slightly dampen near‑term earnings.

Renewal Season: Stable Pricing, Lower Net Rate

Swiss Re renewed treaty contracts totaling USD 12.4 billion in gross premium, with headline pricing broadly flat overall. Mid‑single‑digit rate gains in casualty were offset by similar declines in property, especially nat cat, and after incorporating the 4.6% higher loss assumptions the group reported a net price decrease of 4.3% on renewed business.

Capital Generation Fuels Flexibility

The company generated about USD 4.7 billion of SST capital in 2025, reinforcing its ability to fund both growth and shareholder payouts. Management reiterated that extraordinary buybacks will remain opportunistic, deployed only when quantitative and qualitative hurdles are met, rather than becoming an automatic recurring commitment.

iptiQ Exit Nears Completion

Swiss Re reported substantial progress on its exit from digital platform iptiQ, with most units sold and the remaining EMEA Life & Health book moved into runoff. Management emphasized that the runoff will be managed within previously outlined expectations, removing a strategic distraction and simplifying the group structure.

Life & Health Assumption Changes Hit Earnings

Detailed reviews of underperforming Life & Health portfolios led to negative assumption updates of around USD 650 million for the year, including roughly USD 250 million in the fourth quarter. The adjustments, focused on Australia, Israel and South Korea, reduced the segment’s insurance service result but are intended to reset future profitability on a more realistic footing.

Adverse Life & Health Experience Adds Pressure

On top of assumption changes, adverse experience eroded Life & Health results by about USD 300 million in 2025, with around USD 200 million tied to the same markets under review. The combination of weaker experience and updated assumptions underscores the challenges in parts of the book, even as the overall segment remains profitable.

Revenue Decline Reflects Portfolio Pruning

Group insurance revenue fell to USD 43.1 billion from USD 45.6 billion, a drop of roughly 5.3% year on year. Management attributed the decline to portfolio disposals, renewal decisions and foreign‑exchange moves, and argued that the shift reflects a deliberate focus on earnings quality and risk‑adjusted returns rather than headline volume.

Higher New Business Strain Weighs on Metrics

New business loss, or day‑one strain, rose to about 3% in 2025, above management’s typical 1.5–2% range and higher than the 2.5% seen in 2024. This elevated strain compressed reported insurance service results and highlights that new business remains capital intensive, even if it is expected to be value‑accretive over time.

Greater Nat Cat Retention Raises Volatility

At the January renewals, Swiss Re cut its external retrocession protection for natural catastrophe risks as previously signaled, increasing its net exposure. The move should improve expected returns but also raises potential earnings volatility, putting more weight on disciplined nat cat underwriting and rigorous risk limits.

iptiQ Accounting Drag in the Fourth Quarter

Fourth‑quarter group items included a roughly USD 100 million negative impact related to iptiQ sales, larger than some investors may have anticipated. This one‑off item weighed on quarterly results but is tied to the strategic withdrawal from the business, which management views as largely complete.

Higher Expense Ratio Masked by One‑offs

The reported expense ratio rose from 4.8% to 5.4%, an increase of 0.6 percentage points that might raise eyebrows on efficiency. Management pointed to year‑end accruals and one‑off project costs as drivers and urged investors to focus on full‑year trends, which they say better reflect underlying cost discipline.

Corporate Solutions Faces Man‑made Losses

Within Corporate Solutions, large man‑made claims totaled USD 351 million, slightly exceeding expectations and partly offsetting favorable nat cat experience. Natural catastrophe claims in the unit were USD 148 million below expectations, helping the segment still deliver a strong combined ratio and earnings contribution.

Top‑line Volatility and Weak New Business Growth

Management acknowledged that top‑line and new business flows were volatile in 2025, with some measures showing around 5% negative growth, partly due to FX and disposals. This volatility complicates forecasting of insurance revenue, but leadership reiterated that they prioritise profitability, risk selection and capital efficiency over chasing premium growth.

Outlook and Guidance: Profits and Discipline Ahead

For 2026, Swiss Re reaffirmed its group net income target of USD 4.5 billion and a Life & Health Re net income goal of USD 1.7 billion, alongside combined‑ratio targets below 85% for P&C Re and below 91% for Corporate Solutions. The company plans to maintain its strengthened reserving stance, a USD 2.1 billion nat cat budget and a USD 300 million cost‑saving run‑rate by 2027, while continuing disciplined capital returns from a roughly 250% SST base.

Swiss Re’s earnings call painted the picture of a reinsurer leaning into profitability and capital strength while cleaning up weaker pockets of its portfolio. Record earnings, strong P&C results and sizable shareholder payouts underpin a constructive story, though Life & Health volatility, lower revenues and higher nat cat retention remain key watchpoints for investors.